Kamada Ltd.

Foreign Filer Report • Aug 19, 2020

Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Stud false

����� ��"�	2 380
KAMADA LTD
Corporation no: 511524605	12585
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	19/08/2020
	www.isa.gov.il			www.tase.co.il				Reference:	2020-02-091008	Time of broadcast: 13:56 13:56

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onKamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective

ea125743-6k_kamadaltdEDGAR1_Bannerless_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: TASE	Date of revision of form structure: 04/08/2020
Address: Holtzman 2 4081 , Rehovot 7670402   ISRAEL , Tel: 08-9406472 , Fax: 08-9406473
E-mail address: liorf@kamada.com   Company site: www.kamada.com
Previous names of reporting entity:
Name of the Signatory: Fhima Lior Position of Signatory in the reporting corporation: Director of Finance Name of Employer Company:
Address: Haim holtzman 2 , Rehovot 7670402 Telephone: 08-9913168 Facsimile: 08-9912083 E-mail: liorf@kamada.com 2